MicroPort NeuroScientific Corporation

MicroPort NeuroScientific Corporation engages in the research and development, production, and sale of neuro-interventional medical devices in the People's Republic of China and internationally. The company offers NUMEN, a coil embolization system; NUMEN FR, a coil detachment system; NUMEN Silk; Tubridge, a flow-diverting stent; Willis, an intracranial stent graft system; Comaneci, an adjustable temporary coil embolization; and Rebridge, an intracranial visualized stent for use in the treatment of hemorrhagic stroke. It also offers NeuroGuard, NuFairy, a absorbable coil embolization system; and liquid embolic agent, a cerebral arteriovenous malformations. In addition, the company provides APOLLO, an intracranial stent a balloon-expandable stent to treat intracranial atherosclerotic disease; Bridge, a rapamycin target eluting vertebral artery stent system; and Diveer, an intracranial balloon catheter to treat cerebral atherosclerosis stenosis. Further, it offers Neurohawk, a stent thrombectomy device; X-Track, and distal access catheter product; W-track, an intracranial aspiration catheter; and balloon protection guide catheter; and Tigertriever, an adjustable stent retriever for use in the treatment of acute ischemic stroke. Additionally, the company provides Carotid Stent System, Asahi Neurovascular Guidewires and U-track support catheter. Furthermore, it offers Fastrack Microcatheter System, Veyronwire Neurovascular Guide Wire, 17 Microcatheter, Distal Protection Device, and QUEEN-track Microcatheter, a hydrophilic coating device for stimulation of blood vessels. MicroPort NeuroScientific is transforming neurovascular care with groundbreaking innovations. The company was founded in 2004 and is headquartered in Shanghai, the People's Republic of China. MicroPort NeuroScientific has been at the forefront of neurovascular care. Founded in 2012, and listed in 2022 in HKEX (Stock Code: 2172.HK.). Its comprehensive neuro-interventional devices portfolio encompasses three key domains: hemorrhagic stroke, cerebral atherosclerotic stenosis, and acute ischemic stroke (AIS). With 196+ authorized patents and a presence in over 2800 hospitals, our commitment to innovation is resolute. Our products facilitate more than 100 cerebrovascular stenting procedures daily.